Share this article
CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/
Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, today announced the appointment of Tim Clackson, Ph.D., as Chief Executive Officer and as a member of the Company s Board of Directors. He succeeds interim CEO Iain Dukes, D.Phil., Theseus Co-Founder and OrbiMed Venture Partner, who will serve as Theseus Executive Chairman. I am thrilled to join the team of R&D leaders at Theseus, who have a proven track record and share my passion for oncology innovation, motivated by our direct experience helping change patients lives with targeted therapies, said Dr. Clackson. Collectively, we are leveraging decades of insight to develop innovative medicines to confront the scourge of treatment resistance. With the backing of our top-tier investors, I look forward to realizing Theseus vision to build an industry leading precisi
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Posted on 256
Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos brings more than 20 years of experience in industry and finance to Gemini.
“It is my pleasure to welcome Brian to the team at this exciting time in Gemini’s history right on the heels of our debut as a public company,” said Jason Meyenburg, Chief Executive Officer of Gemini. “Brian’s deep financial experience and results-driven attitude will be invaluable to us as we continue to develop first-in-class medicines, using insights in genetics and biology, to restore regulation of the complement system in the eye and throughout the body.”